These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23821256)

  • 1. A homogeneous time-resolved fluorescence assay to identify inhibitors of HIV-1 fusion.
    Smeulders L; Bunkens L; Vereycken I; Van Acker K; Holemans P; Gustin E; Van Loock M; Dams G
    Methods Mol Biol; 2013; 1030():11-7. PubMed ID: 23821256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion.
    Dams G; Van Acker K; Gustin E; Vereycken I; Bunkens L; Holemans P; Smeulders L; Clayton R; Ohagen A; Hertogs K
    J Biomol Screen; 2007 Sep; 12(6):865-74. PubMed ID: 17644771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
    Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
    J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
    Melikyan GB; Egelhofer M; von Laer D
    J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
    Cai L; Gochin M
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
    Liu S; Boyer-Chatenet L; Lu H; Jiang S
    J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation.
    Zhao L; Hu ZW; Tong P; Chen YX; Zhao YF; Li YM
    Bioorg Med Chem Lett; 2013 May; 23(9):2727-32. PubMed ID: 23522564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
    Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
    Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
    Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM
    Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
    J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.
    Gustchina E; Louis JM; Bewley CA; Clore GM
    J Mol Biol; 2006 Dec; 364(3):283-9. PubMed ID: 17010381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a FRET assay for monitoring of HIV gp41 core disruption.
    Xu Y; Hixon MS; Dawson PE; Janda KD
    J Org Chem; 2007 Aug; 72(18):6700-7. PubMed ID: 17685571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mammalian two-hybrid system-based assay for small-molecular HIV fusion inhibitors targeting gp41.
    Shui X; Lu X; Gao Y; Liu C; Ren F; Jiang Q; Zhang H; Zhao B; Zheng Z
    Antiviral Res; 2011 Apr; 90(1):54-63. PubMed ID: 21352856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.
    Vaillant A; Juteau JM; Lu H; Liu S; Lackman-Smith C; Ptak R; Jiang S
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1393-401. PubMed ID: 16569857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.
    Miyauchi K; Kozlov MM; Melikyan GB
    PLoS Pathog; 2009 Sep; 5(9):e1000585. PubMed ID: 19763181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection.
    Liu D; Wang H; Yamamoto M; Song J; Zhang R; Du Q; Kawaguchi Y; Inoue JI; Matsuda Z
    Retrovirology; 2018 Apr; 15(1):27. PubMed ID: 29609648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C; Liu S; Jiang S
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.
    Jin BS; Lee WK; Ahn K; Lee MK; Yu YG
    J Biomol Screen; 2005 Feb; 10(1):13-9. PubMed ID: 15695339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.